PRIMA1 is a mutant p53 reactivating compound (Bykov et al., 2002) which has been shown to reactivate unfolded p53 mutants to native, functional conformation and, recently, to prevent mutant p53 aggregate accumulation in cancer cells (Rangel et al., 2019). This evidence concerns the gene TP53 and cancer.